We aim for sustainable performance over time to benefit patients, employees, shareholders and society. Solid financial results and maintaining the trust of society underpin our ability to create value.
Investors Event Calendar
Second quarter & Half year 2022 results
Environmental, Social and Governance (ESG)
ESG Updates: July 20, 2022 (PDF 0.4 MB) | Apr 27, 2022 (PDF 0.7 MB) | Feb 03, 2022 (PDF 1.7 MB) | Oct 27, 2021 (PDF 0.5 MB)
Latest updates: Novartis Enterprise Risk Management (PDF 0.2 MB) | Materiality Assessment
We have created a set of environmental, social and governance indices to signpost where our key disclosures can be found across our publications and channels. Novartis aims to report comprehensively and transparently for all stakeholders concerned with ESG topics.
Stocks
Media Releases
Novartis unveils new focused strategy, underpinned by eight potential multi-billion dollar peak sales brands & deep pipeline, at Meet the Management event
Novartis plans to petition the U.S. Supreme Court to uphold validity of the Gilenya® (fingolimod) dosing regimen patent
Sandoz announces further progress on its biosimilar pipeline, with release of positive results for denosumab integrated Phase I/III clinical trial
Pulse Updates
December 16, 2021
Novartis receives FDA Fast Track designation for branaplam (LMI070) for the treatment of Huntington’s Disease
September 28, 2021
FDA grants Priority Review for investigational targeted radioligand therapy 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer (mCRPC)
Investor Relations Contacts
For questions about investor relations or the share registry, please contact our team.
Stay Up-to-Date
Stay connected to the latest news and information from Novartis
Novartis AG
Lichtstrasse 35
CH-4056 Basel, Switzerland